Indeed, two major changes in the management of AML patients had been undertaken in our center during this period of time: the introduction of primary prophylaxis of invasive fungal infections using azoles (voriconazole from 2003 to 2008, posaconazole thereafter) [21] and the stratification of allo-HSCT indication according to the new molecular classification of intermediate-risk AML using CEBPA, FLT3 and NPM1 mutations. This evidence concerns the gene FLT3 and fungal infectious disease.